Linefor

Pregabalin, the active ingredient in Linefor, is a gabapentinoid presented as an oral formulation for oral use. It is employed to manage neuropathic pain, adjunctive therapy for partial seizures, generalized anxiety disorder, and fibromyalgia in adult patients. It is indicated for diabetic peripheral neuropathic pain, post‑herpetic neuralgia, and fibromyalgia, offering pain reduction and improved quality of life.

GNH USA supplies Linefor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable logistics for global distribution.

Pregabalin acts on the nervous system to alleviate various neuropathic and central nervous system disorders.

Diabetic peripheral neuropathic pain: reduces pain intensity and improves functional ability in patients with diabetes‑related nerve damage. Postherpetic neuralgia: alleviates lingering nerve pain following shingles, enhancing daily comfort. Partial seizures (adjunctive therapy): decreases seizure frequency when added to existing antiepileptic regimens. Fibromyalgia: lessens widespread musculoskeletal pain and fatigue, contributing to better sleep and activity levels. Generalized anxiety disorder: diminishes anxiety symptoms, promoting calmer mood and improved coping.

Pregabalin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness or fatigue. - Peripheral edema: swelling of the lower extremities due to fluid retention. - Weight gain: gradual increase in body weight during treatment.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway requiring immediate medical attention. - Severe rash or Stevens‑Johnson syndrome: skin reactions that may be life‑threatening. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

When prescribing pregabalin, clinicians should consider several precautionary measures to ensure patient safety.

Renal impairment: dose adjustment may be required because the drug is excreted unchanged in urine. Elderly patients: increased sensitivity to central nervous system effects; start with lower dose and monitor. History of substance misuse: assess risk of dependence and counsel on appropriate use. Concomitant CNS depressants: avoid or use with caution due to additive sedation. Suicidality monitoring: observe for new or worsening depression, suicidal thoughts, especially during early treatment. Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Pregabalin can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Opioids: combined use may cause profound respiratory depression and excessive sedation; avoid co‑administration. - CNS depressants (e.g., benzodiazepines, alcohol): may intensify sedation and impair cognition; avoid high‑dose combinations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may increase risk of peripheral edema; monitor fluid status. - Diuretics: may enhance hypotensive effects; observe blood pressure. - Anticholinergic agents: may worsen cognitive impairment; assess patient response.